Daniela Zackova

Daniela Žáčková, MD, PhD is Consultant in Hematology and Associate Professor at the Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic. Her scientific interest is mainly focused on clinical and biological aspects of chronic myeloid leukemia (CML). She acts as a PI of the nationwide investigator-initiated TKI discontinuation phase II trial HALF, co-investigator and national coordinator of international projects and trials such as TIGER (CMLV) study, EURO-SKI/AFTER-SKI, PONDEROSA, and Blast Crisis Registry, and expert guarantor and national coordinator of the Czech Registry of CML patients called INFINITY. She is a member of the European Hematology Association (EHA), European LeukemiaNet (ELN) Working package 4 (WP4), Czech Leukemia Study Group for Life (CELL), Advisory Board of the patient supportive organisation „Diagnóza leukemie“ and an elected Chair of the Audit committee of the Czech Hematology Association. She is an author or co-author of more than 70 peer-reviewed articles, 4 scholarly books, and 8 peer-reviewed textbooks or textbook chapters.